Particle Carriers for Combating Multidrug-Resistant Cancer
Open Access
- 11 November 2013
- journal article
- perspective
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 7 (11) , 9512-9517
Abstract
Multidrug resistance (MDR) in tumors accounts for significant treatment failure. Particle carriers offer potential benefits for treating cancer, including the ability to target tumors and to deliver multiple cargo, providing opportunities to overcome drug resistance. In this Perspective, we provide a brief introduction to the MDR mechanisms and implications of tumor heterogeneity that contribute to drug resistance. We also highlight recent advances in the design of particles aimed at treating resistant tumors through particle-based codelivery of therapeutics. Finally, we discuss future directions, where an increased understanding of the tumor biology can be leveraged to develop new and improved particle-based cancer therapies.Keywords
This publication has 28 references indexed in Scilit:
- Layer-by-Layer Nanoparticles for Systemic Codelivery of an Anticancer Drug and siRNA for Potential Triple-Negative Breast Cancer TreatmentACS Nano, 2013
- Genetic heterogeneity and cancer drug resistanceThe Lancet Oncology, 2012
- Nanoparticle Delivery of Cancer DrugsAnnual Review of Medicine, 2012
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implicationsThe Lancet Oncology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- ABC transporters in cancer: more than just drug efflux pumpsNature Reviews Cancer, 2010
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2007
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Chemotherapy and the war on cancerNature Reviews Cancer, 2005